<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479504</url>
  </required_header>
  <id_info>
    <org_study_id>GuangxiMU</org_study_id>
    <nct_id>NCT01479504</nct_id>
  </id_info>
  <brief_title>A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>303rd Hospital of the People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanning Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Traditional Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guilin Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Naxishan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Worker's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Railway hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Yulin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Red Cross hospital of YuLin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guigang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Red Cross hospital of Wuzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter trial.The primary objective is to estimate short-term efficacy
      and acute toxicities of nedaplatin to the combination of docetaxel in neoadjuvant
      chemotherapy followed by nedaplatin in concurrent chemoradiotherapy, compared to cisplatin to
      the combination of docetaxel in neoadjuvant chemotherapy followed by cisplatin in concurrent
      chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.

      Secondary objectives are to evaluate the overall survival, the distant metastases free
      survival, and disease free survival of patients with locoregionally advanced nasopharyngeal
      carcinoma treated with these regimens.Furthermore,analyze the cost-effectiveness of the
      regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with clinical stage T3-4N1/N2-3 (UICC 7th edition)are divided into two groups
      according to informed consent:intensity-modulated radiation therapy（IMRT）group and
      conventional fractionation radiotherapy(CRT)group. Then the patients in IMRT group/CRT group
      are randomly assigned to receive nedaplatin+docetaxel in neoadjuvant chemotherapy plus
      nedaplatin alone in concurrent chemoradiotherapy or cisplatin+docetaxel in neoadjuvant
      chemotherapy plus cisplatin alone in concurrent chemoradiotherapy.Evaluate the overall
      survival, the distant metastases free survival, and disease free survival of the patients
      treated with these regimens.Furthermore,analyze the cost-effectiveness of the regimens.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response (CR) rate</measure>
    <time_frame>3 months</time_frame>
    <description>3 months after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Acute toxicity will be measured by CTCAE3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1,3,5 years</time_frame>
    <description>1 years，3 years and 5 years overall survival,disease free survival,distant metastases free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness ratio</measure>
    <time_frame>3 months</time_frame>
    <description>Calculate the cost(C) and complete response rate(E) of each group 3 months after treatment,then calculate cost-effectiveness ratio(C/E).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>1A(nedaplatin and IMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B(cisplatin and IMRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A(nedaplatin and CRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B((cisplatin and CRT))</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nedaplatin and docetaxel</intervention_name>
    <description>neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy</description>
    <arm_group_label>1A(nedaplatin and IMRT)</arm_group_label>
    <other_name>TN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and docetaxel</intervention_name>
    <description>neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy</description>
    <arm_group_label>1B(cisplatin and IMRT)</arm_group_label>
    <other_name>TP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nedaplatin and docetaxel</intervention_name>
    <description>neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy</description>
    <arm_group_label>2A(nedaplatin and CRT)</arm_group_label>
    <other_name>TN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and docetaxel</intervention_name>
    <description>neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy</description>
    <arm_group_label>2B((cisplatin and CRT))</arm_group_label>
    <other_name>TP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven nasopharyngeal carcinoma for primary treatment with radical
             intent

          -  non-keratinizing or undifferentiated type

          -  clinical stage III-IVb (UICC 7th edition)

          -  age between 18-70

          -  satisfactory performance status: Karnofsky scale (KPS) &gt; 70.

          -  hemoglobin &gt; 100g/L, WBC &gt; 4.0x10*9/L, Plt &gt; 100x10*9/L

          -  serum creatinine level &lt; 1.6 mg/dL or creatinine clearance ≥ 60 mL/min.

          -  normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)
             ≤2.5×ULN, and bilirubin ≤1.5ULN

          -  patients must be informed of the investigational nature of this study and give written
             informed consent.

          -  anticipated life span more than 6 month

        Exclusion Criteria:

          -  primary treatment with palliative intent

          -  WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma
             Evidence of distant metastases

          -  pregnancy or lactation

          -  history of previous radiotherapy (except for non-melanomatous skin cancers outside
             intended RT treatment volume).

          -  prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes

          -  prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             in-situ cervical cancer or other cancer for which the patient has been disease-free
             for 5 years

          -  any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), and emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang R. sheng, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Radiotherapy，the First Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang R sheng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiotherapy，the First Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wu Fang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiotherapy，the First Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang R Sheng, M.D.</last_name>
    <phone>86(0771)3276223</phone>
    <email>wrsgx@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wu Fang, M.D.</last_name>
    <phone>86(0771)3276313</phone>
    <email>96160f@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiotherapy，the First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang R Sheng, M.D.</last_name>
      <phone>8613807806008</phone>
      <email>wrsgx@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wu Fang, M.D.</last_name>
      <phone>8613978880156</phone>
      <email>96160f@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wang R Sheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wu Fang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <last_update_submitted>November 24, 2011</last_update_submitted>
  <last_update_submitted_qc>November 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Wang Rensheng</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <keyword>Nedaplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nedaplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

